semaglutide oral cardiovascular indication news 2025 in High-Risk Type 2 Diabetes: Benefit Confirmed in the SOUL Trial FDA approves oral semaglutide for
Description
In patients with T2D at high CV risk in PIONEER 6, oral semaglutide reduced HbA 1c compared with placebo as an add-on to standard of care (mean change of 1.0% vs 0.3%) at the end of the trial (not statistically analyzed
GLP-1 and GIP receptor agonists work by increasing the amount of insulin that the pancreas releases in response to food, while decreasing the amount of sugar the liver releases into the blood and slows food leaving the stomach after eating
View Article PubMed Central
Do not do that for your main lifts
Semaglutide can only be prescribed by a qualified weight loss specialist, ensuring appropriate usage
Blomstrand, R
